---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-24-000053"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:50:28.788064+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "medium"
source: SEC EDGAR
---

# Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery

## Summary
- Filed a provisional patent application with the USPTO on February 7, 2024.
- Covers compositions, protocols, and treatment means for accelerating hematopoietic reconstitution.
- Targets recovery after insult or chronic pathology using stem cell-derived endothelial progenitor or endothelial cells.
- Application protects a potential regenerative medicine therapy for bone marrow or blood cell restoration.

## SEC filing metadata
- accession: 0001607062-24-000053
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/0001607062-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/rgbp020924form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-24-000053
- JSON: https://secwatch.observer/filing/0001607062-24-000053.json
- Plain text: https://secwatch.observer/filing/0001607062-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.